CorMedix Reports Strong Q4 & Full-Year 2025 Results, Reiterates 2026 Guidance
Summary
CorMedix Inc. announced robust financial results for Q4 and full-year 2025, reporting significant revenue growth and a substantial shift to profitability, while reaffirming its positive 2026 guidance.
Key Events
-
Strong Q4 2025 Financial Performance
CorMedix reported net revenue of $128.6 million and net income of $14.0 million for the fourth quarter of 2025, significantly up from the comparable period in 2024.
-
Significant Full-Year Profitability Turnaround
For the full year 2025, the company achieved total revenue of $311.7 million (pro forma $401.3 million) and a net income of $163.0 million, a substantial improvement from a net loss of $17.9 million in 2024.
-
2026 Guidance Reaffirmed
CorMedix reiterated its previously established guidance for fiscal year 2026, projecting net revenue between $300 million and $320 million and adjusted EBITDA between $100 million and $125 million.
-
Healthy Cash Position
The company ended December 31, 2025, with $148.5 million in cash and short-term investments, excluding restricted cash.
Analysis
CorMedix Inc. announced robust financial results for the fourth quarter and full-year 2025, marking a significant turnaround to profitability driven by strong DefenCath sales and the Melinta acquisition. The substantial net income for the full year, compared to a loss in the prior year, signals successful integration and commercial execution. The reaffirmation of positive 2026 guidance provides a clear outlook for continued growth and profitability, reinforcing investor confidence. Additionally, the company highlighted upcoming clinical data for REZZAYO in Q2 2026, which could serve as a significant near-term catalyst.
At the time of this filing, CRMD was trading at $6.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $561M. The 52-week trading range was $5.60 to $17.43. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.